feedback

Course Director

Daniel J. DeAngelo, MD, PhD
Daniel J. DeAngelo, MD, PhD

Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty

Stephan A. Grupp
Stephan A. Grupp, MD, PhD

University of Pennsylvania Perelman School of Medicine
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Mark R. Litzow
Mark R. Litzow, MD

Mayo Clinic
Rochester, Minnesota

Charles Mullighan
Charles Mullighan, MBBS, MD

St. Jude Children’s Research Hospital
Memphis, Tennessee

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:2.0 Credits
Release Date:2018-Jan-11
Expiration Date:2019-Jan-10
Estimated Time for Completion:120 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity based on a live symposium held at the 2017 American Society of Hematology Annual Meeting and Exposition, experts in the management of acute lymphoblastic leukemia (ALL) offer insights on recent prognostic and therapeutic innovations, including updated evidence on the use of novel antibody technologies and chimeric antigen receptor (CAR)-T cell therapy. The panel also discusses real-world experience with these innovative treatments, and assesses a future in which sequential and combination approaches may offer further improvements in patient care.

Upon completion of this activity, participants should be better able to:
  • Describe the mechanisms of novel antibody-based therapies in ALL, including antibody-drug conjugates, bispecific agents, and other options
  • Summarize efficacy evidence on the use of antibody- and immune-based therapy in ALL, including in relapsed/refractory disease or patients with persistent minimal residual disease (MRD)
  • Recommend patient-appropriate antibody therapy for individuals with ALL who present with relapsed disease or persistent MRD
  • Cite updated evidence on novel strategies combining antibody-based therapy with other treatment modalities in the ALL setting, including in newly diagnosed patients
  • Manage treatment-related toxicity in patients with ALL receiving novel therapeutics, including antibody-based treatment

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, advanced practice oncology nurses, and other healthcare professionals involved in the care of patients with ALL.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: January 11, 2018 - January 10, 2019
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Daniel J. DeAngelo, MD, PhD
Director of Clinical and Translational Research, Adult Leukemia
Institute Physician
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Stephan A. Grupp, MD, PhD
Novotny Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Director, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Frontier Program
CCCR Director of Translational Research
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Stephan A. Grupp, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Jazz Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Novartis Pharmaceuticals Corporation.

Mark R. Litzow, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Mark R. Litzow, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen.
Grant/Research Support from Amgen; Astellas Pharma US, Inc.; and Novartis Pharmaceuticals Corporation.

Charles Mullighan, MBBS, MD
Member, Department of Pathology
Co-Leader, Hematological Malignancies Program
St. Jude Children’s Research Hospital
Memphis, Tennessee

Charles Mullighan, MBBS, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Loxo Oncology.
Speakers Bureau participant with Amgen Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6150-18-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.